CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands ...

The FDA first approved Zepbound to treat obesity in November 2023. Its active ingredient, tirzepatide, was previously ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly's blockbuster drugs ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...